The Motley Fool··Adria CiminoIovance Biotherapeutics Expands Market Presence Following Amtagvi Approval
Iovance's newly approved melanoma therapy Amtagvi generated $68M in quarterly revenue with strong 52% response rates, positioning the biotech for pipeline expansion across multiple cancer indications.
IOVAbiotechclinical trials